Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

Basel: Roche has announced that the company has received approval from the European Commission for Columvi (glofitamab) in ...

BriaPro has filed US patent applications for this technology ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address autoimmune and inflammatory conditions.

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal ... more than 2.3 million people have a diagnosis of MS. 1 This press ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...